JUPITER, Fla.--(BUSINESS WIRE)--Envoy Therapeutics, Inc., a newly formed drug discovery company, today announced that it has secured a loan from Takeda Research Investment (TRI) which Envoy may elect to convert to Envoy preferred stock should the company complete a second private equity financing. TRI will receive certain rights from Envoy related to a specific therapeutic field while scientists at the two companies craft a broad scientific research alliance.
